P = 0.0640)
ZEPBOUND- tirzepatide injection, solution ZEPBOUND- tirzepatide injection, solution ZEPBOUND KWIKPEN- tirzepatide injection, solution Eli Lilly and Company ---------- ZEPBOUND is indicated in combination with a reduced-calorie diet and increased physical activity: Injection: Clear, colorless to slightly yellow solution in pre-filled single-dose pens, single-dose vials, multi-dose vials, or single-patient-use KwikPens, each available in the following strengths
Five milligrams is five milligrams
Simultaneously, tirzepatide's GLP-1 receptor agonist activity promotes glucose-dependent insulin secretion, inhibits glucagon release, and may influence gastric emptying in experimental settings
Switching Requires Medical Guidance: Transitioning involves stopping the first medication, potentially having a washout period, and starting the new medication (Zepbound) at the lowest dose, followed by gradual titration under a provider's supervision
Tirzepatide mechanism of action is thought to involve the activation of specific receptors in the brain that regulate appetite and metabolism